Q1 Earnings Estimate for Pfizer Issued By Leerink Partnrs

Pfizer Inc. (NYSE:PFE) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Pfizer in a research note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst D. Risinger anticipates that the biopharmaceutical company will post earnings of $0.58 per share for the quarter. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer’s Q3 2025 earnings at $1.05 EPS, FY2025 earnings at $2.82 EPS, FY2026 earnings at $3.14 EPS, FY2027 earnings at $3.09 EPS and FY2028 earnings at $2.73 EPS.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.17) EPS.

A number of other brokerages have also weighed in on PFE. Guggenheim decreased their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $32.15.

Pfizer Stock Performance

PFE stock opened at $25.58 on Friday. The firm has a market cap of $144.96 billion, a price-to-earnings ratio of 34.57, a PEG ratio of 0.63 and a beta of 0.65. Pfizer has a twelve month low of $24.48 and a twelve month high of $31.54. The business’s fifty day simple moving average is $27.17 and its two-hundred day simple moving average is $28.27. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.72%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 232.43%.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PFE. Gladius Capital Management LP lifted its position in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the period. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Quarry LP purchased a new stake in Pfizer in the 2nd quarter valued at approximately $31,000. Financial Connections Group Inc. acquired a new stake in Pfizer during the 2nd quarter valued at $34,000. Finally, Teachers Insurance & Annuity Association of America purchased a new stake in shares of Pfizer in the third quarter valued at $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.